Targeting the p53 Pathway in CLL: State of the Art and Future Perspectives
Open Access
Abstract
The p53 pathway is a desirable therapeutic target, owing to its critical role in the maintenance of genome integrity. This is exemplified in chronic lymphocytic leukemia (CLL), one of the most common adult hematologic malignancies, in which functional loss of p53 arising from genomic aberrations are frequently associated with clonal evolution, disease progression, and therapeutic resistance, even in the contemporary era of CLL targeted therapy and immunotherapy. Targeting the ‘undruggable’ p53 pathway therefore arguably represents the holy grail of cancer research. In recent years, several strategies have been proposed to exploit p53 pathway defects for cancer treatment. Such strategies include upregulating wild-type p53, restoring tumor suppressive function in mutant p53, inducing synthetic lethality by targeting collateral genome maintenance pathways, and harnessing the immunogenicity of p53 pathway aberrations. In this review, we will examine the biological and clinical implications of p53 pathway defects, as well as our progress towards development of therapeutic approaches targeting the p53 pathway, specifically within the context of CLL. We will appraise the opportunities and pitfalls associated with these therapeutic strategies, and evaluate their place amongst the array of new biological therapies for CLL.Keywords
Funding Information
- Cancer Research UK (C20807/A2864)
This publication has 197 references indexed in Scilit:
- The novel cyclin-dependent kinase inhibitor dinaciclib (SCH727965) promotes apoptosis and abrogates microenvironmental cytokine protection in chronic lymphocytic leukemia cellsLeukemia, 2012
- The role of PARP in DNA repair and its therapeutic exploitationBritish Journal of Cancer, 2011
- Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid LeukemiaNew England Journal of Medicine, 2011
- Acquisition of p53 mutations in response to the non-genotoxic p53 activator Nutlin-3Oncogene, 2011
- Chk1 inhibits replication factory activation but allows dormant origin firing in existing factoriesJournal of Cell Biology, 2010
- ATM activates the pentose phosphate pathway promoting anti‐oxidant defence and DNA repairThe EMBO Journal, 2010
- Glutaminase 2, a novel p53 target gene regulating energy metabolism and antioxidant functionProceedings of the National Academy of Sciences, 2010
- ATR: an essential regulator of genome integrityNature Reviews Molecular Cell Biology, 2008
- Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibitionProceedings of the National Academy of Sciences, 2008
- Cell death by mitotic catastrophe: a molecular definitionOncogene, 2004